A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Krishnansu Tewari, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UC Irvine
- Krishnansu Tewari, MD
Professor, Obstetrics and Gynecology. Authored (or co-authored) 189 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Links
- VBL Therapeutics Company Website OVAL study Website
- ID
- NCT03398655
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated